Lv4
464 积分 2025-11-10 加入
Evolution of drug resistance against antiviral agents that target cellular factors
12小时前
待确认
The four Ws of viruses: Where, Which, What and Why - A deep dive into viral evolution
17小时前
求助中
Structural and nonstructural proteins of Senecavirus A: Recent research advances, and lessons learned from those of other picornaviruses
17小时前
已完结
First-in-human study to assess the safety, pharmacokinetics, and pharmacodynamics of ARV-102, a PROTAC LRRK2 degrader, in healthy volunteers
2天前
已完结
Exploring LRRK2-dependent Mechanisms in Parkinson’s Disease Therapy
3天前
已关闭
Research progress of PROTACs for neurodegenerative diseases therapy
4天前
已完结
Discovery of the First Clinical Protein Degrader for the Treatment of Autoimmune Indications: Orally Bioavailable and Selective IRAK4 Degrader KT-474
5天前
已完结
BGB-45035, a selective IRAK4 CDAC, demonstrated fast IRAK4 degradation and strong signaling inhibition, and superior efficacy in preclinical disease models 2529
5天前
已完结
IRAK family in inflammatory autoimmune diseases
5天前
已完结
252 Safety, Pharmacokinetics and Pharmacodynamics of KT-621, an Oral STAT6 Degrader, in Healthy Adults
6天前
已关闭
皖公网安备34019202002308
